Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16237 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Yuko Kanbayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Adverse Drug Reaction Reporting Systems, Databases, Factual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: No funding was received for this study, Taiho Pharmaceutical.
Themen: Patientensicherheit
Abstract (Originalsprache)
Aims
This study was conducted to examine disproportionality, times to onset, incidence rates and outcomes of lenvatinib‐associated cardiac adverse events (AEs) using the Japanese Adverse Drug Event Report database.
Methods
We analysed data for the period between April 2004 and May 2023. Data on cardiac AEs were extracted and the relative disproportionality of AEs was estimated using reporting odds ratios (RORs). Furthermore, Weibull distribution parameters were calculated.
Results
Of the 2 230 863 reports analysed, we identified 7684 reports of AEs associated with lenvatinib, including 317 cardiac AEs. Signals were detected for eight cardiac AEs: hypertension, cardiac failure, myocarditis, myocardial infarction, immune‐mediated myocarditis, cardiomyopathy, angina unstable and cardiotoxicity. Among these, fatal outcomes were observed for cardiac failure, myocarditis and myocardial infarction. Histograms of median times to onset for the eight detected cardiac AE signals showed that AEs occurred at a median of 3.5–134.5 days after lenvatinib administration. The Weibull distributions showed that cardiac failure occurred early after administration (early failure type), myocarditis occurred in a dose‐dependent manner (wearout failure type), and myocardial infarction occurred constantly throughout the exposure period (random failure type).
Conclusions
We focused on cardiac AEs associated with lenvatinib as post‐marketing AEs. Serious outcomes can arise after lenvatinib administration. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but also over an extended period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
- School of Pharmacy, Hyogo Medical University, Kobe, Japan.
ORCID-Profile: Yuko Kanbayashi
Förderung
- No funding was received for this study
- Taiho Pharmaceutical
Zitieren
APA
Kanbayashi, Y., Kobayashi, S., Kojima, A., Wakabayashi, H., Shimizu, T., & Uchida, M. (2024). Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16237
Vancouver
Kanbayashi Y, Kobayashi S, Kojima A, Wakabayashi H, Shimizu T, Uchida M. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16237
BibTeX
@article{Kanbayashi2024,
author = {Kanbayashi, Yuko and Kobayashi, Sakura and Kojima, Asuka and Wakabayashi, Haruka and Shimizu, Tadashi and Uchida, Mayako},
title = {Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16237}
}
EUVIMED